The National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Dolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen.
A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.
CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.
Patients randomized to acyclovir MBT experienced less time from prodromal symptoms to healing; more patients had abortive episodes that did not progress to vesicular lesions; and duration of abortive episodes was briefer.
ORBIT-AF study results indicate that the benefit of adding aspirin therapy to oral anticoagulation for atrial fibrillation patients is unclear.
Study results were based on laboratory-confirmed hospital cases of pneumonia with and without influenza, in 2,320 children and adults. Many previous studies lacked either laboratory confirmation or vaccine status.
Before the approval of riociguat, there was no approved nonsurgical therapy for chronic thromboembolic pulmonary hypertension.
Alogliptin approved as monotherapy and in two combinations